Koji Haratani, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Non-Small-Cell Lung | 28 | 2024 | 5302 | 2.120 |
Why?
|
| Lung Neoplasms | 30 | 2024 | 13337 | 1.540 |
Why?
|
| Receptor, erbB-3 | 6 | 2021 | 143 | 1.270 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2019 | 101 | 0.620 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2018 | 161 | 0.560 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 3 | 2020 | 1090 | 0.560 |
Why?
|
| Antibodies, Monoclonal | 5 | 2024 | 9179 | 0.550 |
Why?
|
| Immune System Diseases | 1 | 2018 | 257 | 0.510 |
Why?
|
| Immunoconjugates | 2 | 2020 | 954 | 0.490 |
Why?
|
| Neoplasms, Experimental | 1 | 2020 | 1230 | 0.470 |
Why?
|
| Drug Resistance, Neoplasm | 10 | 2023 | 5305 | 0.470 |
Why?
|
| Acrylamides | 1 | 2015 | 259 | 0.450 |
Why?
|
| Protein Kinase Inhibitors | 11 | 2022 | 5665 | 0.440 |
Why?
|
| Tumor Microenvironment | 5 | 2023 | 3874 | 0.430 |
Why?
|
| Pyrimidines | 2 | 2021 | 3027 | 0.300 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2020 | 8545 | 0.290 |
Why?
|
| Camptothecin | 2 | 2021 | 590 | 0.280 |
Why?
|
| Mutation | 15 | 2023 | 30045 | 0.270 |
Why?
|
| Carcinoma, Squamous Cell | 4 | 2021 | 4021 | 0.260 |
Why?
|
| Receptor, erbB-2 | 4 | 2021 | 2557 | 0.240 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 7 | 2022 | 11740 | 0.230 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2022 | 1743 | 0.230 |
Why?
|
| Exodeoxyribonucleases | 1 | 2024 | 192 | 0.210 |
Why?
|
| Xenograft Model Antitumor Assays | 6 | 2020 | 3602 | 0.210 |
Why?
|
| Genital Neoplasms, Male | 1 | 2021 | 68 | 0.190 |
Why?
|
| Antineoplastic Agents | 6 | 2020 | 13637 | 0.190 |
Why?
|
| Paget Disease, Extramammary | 1 | 2021 | 51 | 0.190 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2021 | 132 | 0.180 |
Why?
|
| Proto-Oncogene Proteins c-met | 2 | 2022 | 570 | 0.180 |
Why?
|
| Cell Line, Tumor | 10 | 2024 | 16979 | 0.180 |
Why?
|
| Gene Amplification | 2 | 2022 | 1088 | 0.170 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2023 | 4510 | 0.170 |
Why?
|
| Neuregulin-1 | 2 | 2019 | 135 | 0.170 |
Why?
|
| Monitoring, Immunologic | 1 | 2019 | 98 | 0.160 |
Why?
|
| Pneumonia | 2 | 2021 | 2140 | 0.160 |
Why?
|
| Aged, 80 and over | 10 | 2024 | 58956 | 0.160 |
Why?
|
| Adenocarcinoma | 2 | 2017 | 6339 | 0.160 |
Why?
|
| Neoplasm Staging | 2 | 2024 | 11106 | 0.160 |
Why?
|
| Hepatitis | 1 | 2020 | 229 | 0.150 |
Why?
|
| Neoplasms | 4 | 2024 | 22164 | 0.150 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2019 | 6479 | 0.150 |
Why?
|
| Carbazoles | 1 | 2019 | 220 | 0.140 |
Why?
|
| Humans | 46 | 2024 | 761423 | 0.140 |
Why?
|
| Melanoma, Experimental | 1 | 2020 | 560 | 0.140 |
Why?
|
| Tamoxifen | 1 | 2021 | 965 | 0.140 |
Why?
|
| Borrelia Infections | 1 | 2016 | 17 | 0.140 |
Why?
|
| Aged | 19 | 2024 | 169235 | 0.140 |
Why?
|
| Maytansine | 1 | 2016 | 86 | 0.130 |
Why?
|
| Patient Selection | 2 | 2019 | 4244 | 0.130 |
Why?
|
| Borrelia | 1 | 2016 | 66 | 0.130 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2018 | 615 | 0.130 |
Why?
|
| Cholangitis | 1 | 2017 | 111 | 0.130 |
Why?
|
| Lyme Neuroborreliosis | 1 | 2016 | 50 | 0.130 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2023 | 2423 | 0.130 |
Why?
|
| Signal Transduction | 5 | 2024 | 23441 | 0.130 |
Why?
|
| Middle Aged | 19 | 2024 | 220826 | 0.130 |
Why?
|
| Phosphoproteins | 1 | 2024 | 2448 | 0.120 |
Why?
|
| Carboplatin | 3 | 2022 | 794 | 0.110 |
Why?
|
| Meningitis, Bacterial | 1 | 2016 | 221 | 0.110 |
Why?
|
| Immunomodulation | 1 | 2018 | 548 | 0.110 |
Why?
|
| Retrospective Studies | 11 | 2023 | 80582 | 0.110 |
Why?
|
| Disease Progression | 3 | 2022 | 13502 | 0.110 |
Why?
|
| Female | 22 | 2024 | 392581 | 0.110 |
Why?
|
| Prognosis | 8 | 2021 | 29620 | 0.100 |
Why?
|
| Japan | 3 | 2021 | 1371 | 0.100 |
Why?
|
| Indoles | 1 | 2020 | 1832 | 0.100 |
Why?
|
| Esophageal Neoplasms | 1 | 2022 | 1649 | 0.100 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2018 | 1355 | 0.100 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2019 | 1651 | 0.100 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2019 | 1624 | 0.100 |
Why?
|
| Treatment Outcome | 8 | 2021 | 64651 | 0.100 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2021 | 2054 | 0.100 |
Why?
|
| Male | 20 | 2024 | 360736 | 0.100 |
Why?
|
| Cisplatin | 3 | 2022 | 1650 | 0.090 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2018 | 1784 | 0.090 |
Why?
|
| Fatal Outcome | 1 | 2015 | 1834 | 0.090 |
Why?
|
| Piperazines | 1 | 2021 | 2523 | 0.090 |
Why?
|
| Adult | 11 | 2024 | 221148 | 0.090 |
Why?
|
| Piperidines | 1 | 2019 | 1656 | 0.090 |
Why?
|
| Quinazolines | 1 | 2016 | 1371 | 0.090 |
Why?
|
| Disease-Free Survival | 2 | 2017 | 6814 | 0.090 |
Why?
|
| Lymphocytes | 1 | 2017 | 2611 | 0.080 |
Why?
|
| Leukocytes | 1 | 2017 | 2028 | 0.080 |
Why?
|
| Pyridines | 1 | 2021 | 2875 | 0.080 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2018 | 3514 | 0.080 |
Why?
|
| Renal Dialysis | 1 | 2019 | 1797 | 0.080 |
Why?
|
| Mice | 9 | 2024 | 81509 | 0.080 |
Why?
|
| Immunohistochemistry | 2 | 2019 | 11073 | 0.080 |
Why?
|
| 1-Alkyl-2-acetylglycerophosphocholine Esterase | 1 | 2008 | 127 | 0.080 |
Why?
|
| Dyneins | 1 | 2008 | 124 | 0.080 |
Why?
|
| Membrane Proteins | 1 | 2024 | 7856 | 0.070 |
Why?
|
| Fluorouracil | 2 | 2022 | 1639 | 0.070 |
Why?
|
| Stomach Neoplasms | 1 | 2016 | 1459 | 0.070 |
Why?
|
| Head and Neck Neoplasms | 1 | 2021 | 2892 | 0.070 |
Why?
|
| Follow-Up Studies | 4 | 2021 | 39117 | 0.060 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2015 | 2824 | 0.060 |
Why?
|
| Survival Rate | 4 | 2021 | 12720 | 0.060 |
Why?
|
| Neutrophils | 1 | 2017 | 3766 | 0.060 |
Why?
|
| Animals | 10 | 2024 | 168441 | 0.060 |
Why?
|
| Cytoplasm | 1 | 2008 | 1511 | 0.060 |
Why?
|
| Ligands | 2 | 2022 | 3271 | 0.060 |
Why?
|
| Paclitaxel | 2 | 2021 | 1732 | 0.060 |
Why?
|
| Gene Expression Profiling | 1 | 2019 | 9418 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 2 | 2021 | 6132 | 0.050 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2008 | 1076 | 0.050 |
Why?
|
| Lung | 1 | 2021 | 9995 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2021 | 9277 | 0.050 |
Why?
|
| Immunotherapy | 1 | 2018 | 4650 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2024 | 54415 | 0.050 |
Why?
|
| Oxycodone | 1 | 2023 | 139 | 0.050 |
Why?
|
| 5'-Nucleotidase | 1 | 2022 | 161 | 0.050 |
Why?
|
| Catechol O-Methyltransferase | 1 | 2023 | 251 | 0.050 |
Why?
|
| Interferons | 1 | 2024 | 705 | 0.040 |
Why?
|
| Breast Neoplasms | 2 | 2019 | 21012 | 0.040 |
Why?
|
| Genes, ras | 1 | 2022 | 654 | 0.040 |
Why?
|
| Time Factors | 2 | 2021 | 39975 | 0.040 |
Why?
|
| Taxoids | 1 | 2022 | 667 | 0.040 |
Why?
|
| Phenotype | 1 | 2017 | 16606 | 0.040 |
Why?
|
| Colorectal Neoplasms | 1 | 2019 | 6935 | 0.040 |
Why?
|
| Plasma Exchange | 1 | 2020 | 158 | 0.040 |
Why?
|
| HT29 Cells | 1 | 2019 | 193 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2021 | 629 | 0.040 |
Why?
|
| Albumins | 1 | 2021 | 575 | 0.040 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2021 | 754 | 0.040 |
Why?
|
| Cell Proliferation | 3 | 2020 | 10441 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2021 | 3639 | 0.040 |
Why?
|
| Morphine | 1 | 2023 | 656 | 0.040 |
Why?
|
| Apoptosis | 3 | 2020 | 9488 | 0.040 |
Why?
|
| DNA Topoisomerases, Type I | 1 | 2018 | 106 | 0.040 |
Why?
|
| Topoisomerase I Inhibitors | 1 | 2018 | 70 | 0.040 |
Why?
|
| HCT116 Cells | 1 | 2019 | 404 | 0.040 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2022 | 4575 | 0.030 |
Why?
|
| Oncogene Protein v-akt | 1 | 2016 | 129 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 2021 | 1703 | 0.030 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2016 | 197 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2021 | 1890 | 0.030 |
Why?
|
| Drug Compounding | 1 | 2017 | 246 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2017 | 17912 | 0.030 |
Why?
|
| Ceftriaxone | 1 | 2016 | 175 | 0.030 |
Why?
|
| Carrier Proteins | 1 | 2008 | 4936 | 0.030 |
Why?
|
| Bronchoscopy | 1 | 2021 | 909 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2018 | 41446 | 0.030 |
Why?
|
| Killer Cells, Natural | 1 | 2024 | 2203 | 0.030 |
Why?
|
| Immunologic Factors | 1 | 2024 | 1588 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 2017 | 1380 | 0.030 |
Why?
|
| Doxycycline | 1 | 2016 | 344 | 0.030 |
Why?
|
| Safety | 1 | 2019 | 1150 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2021 | 4852 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2021 | 2914 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2021 | 2455 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2019 | 3614 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2021 | 2863 | 0.030 |
Why?
|
| Facial Paralysis | 1 | 2016 | 345 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 1 | 2018 | 1486 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 1 | 2022 | 2826 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2018 | 2918 | 0.020 |
Why?
|
| Single-Cell Analysis | 1 | 2022 | 2449 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2021 | 4741 | 0.020 |
Why?
|
| Antibodies, Bacterial | 1 | 2016 | 1469 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2019 | 6215 | 0.020 |
Why?
|
| Biopsy | 1 | 2021 | 6766 | 0.020 |
Why?
|
| Disease Models, Animal | 2 | 2019 | 18247 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2021 | 10089 | 0.020 |
Why?
|
| Cell Survival | 1 | 2019 | 5790 | 0.020 |
Why?
|
| Fluorescence Recovery After Photobleaching | 1 | 2008 | 54 | 0.020 |
Why?
|
| Genetic Testing | 1 | 2021 | 3538 | 0.020 |
Why?
|
| Genotype | 1 | 2023 | 13009 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2021 | 12058 | 0.020 |
Why?
|
| Pain | 1 | 2023 | 5071 | 0.020 |
Why?
|
| Genomics | 1 | 2023 | 5820 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2018 | 8320 | 0.020 |
Why?
|
| Antibodies, Neutralizing | 1 | 2017 | 1943 | 0.020 |
Why?
|
| Analgesics, Opioid | 1 | 2023 | 3804 | 0.020 |
Why?
|
| Gene Expression | 1 | 2019 | 7584 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2018 | 2811 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2016 | 6309 | 0.020 |
Why?
|
| Tubulin | 1 | 2008 | 693 | 0.010 |
Why?
|
| Biological Transport | 1 | 2008 | 2092 | 0.010 |
Why?
|
| Incidence | 1 | 2021 | 21341 | 0.010 |
Why?
|
| Microtubules | 1 | 2008 | 1074 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2020 | 22163 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 15838 | 0.010 |
Why?
|
| Liver | 1 | 2017 | 7532 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2008 | 3734 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2021 | 23990 | 0.010 |
Why?
|
| Swine | 1 | 2008 | 5914 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2016 | 7409 | 0.010 |
Why?
|
| Cell Line | 1 | 2008 | 15605 | 0.010 |
Why?
|
| Risk Factors | 1 | 2021 | 74167 | 0.010 |
Why?
|
| Neurons | 1 | 2008 | 9462 | 0.010 |
Why?
|